SequelSEC

Matinas BioPharma Holdings, Inc. MTNB

Pharmaceutical Preparations · CIK 0001582554 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$5.89M
Fiscal year ended 2023-12-31
Free cash flow
-$4.58M
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$4.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.70Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue451.5%85th
CapEx / revenue19.9%85th
Revenue YoY growth-65.6%20th
FCF margin-1413.9%20th
R&D / revenue1322.0%78th
Net margin-2093.2%24th
Operating margin-2168.4%25th
Current ratio5.93x64th

Matinas BioPharma Holdings, Inc. (MTNB) reported revenue of $0 and net income of -$5.31M for the fiscal year ended 2023-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Matinas BioPharma Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Matinas BioPharma Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-312021-09-302021-06-30
Revenue$0$0$0$1.10M$1.06M$1.06M$1.06M-$333$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$5.89M-$6.13M-$6.16M-$5.59M-$5.48M-$5.46M-$5.92M-$6.71M-$6.88M-$4.79M
Net income-$5.31M-$6.06M-$6.06M-$5.51M-$3.63M-$5.46M-$5.92M-$6.70M-$6.84M-$4.79M
Research & development$3.66M$3.30M$3.56M$3.97M$3.87M$3.71M$4.13M$4.24M$4.62M$2.48M
Weighted-average diluted sharesUnavailableshares 4.35Mshares 217.26Mshares 217.26MUnavailableshares 216.86Mshares 216.86MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-1.39$-0.03$-0.03Unavailable$-0.03$-0.03UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.22M$2.84M$2.60M$2.71M$2.68M$2.82M$2.86M$2.47M$2.26M$2.31M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Matinas BioPharma Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-312021-09-302021-06-30
Cash & equivalents$4.79M$6.41M$9.74M$5.74M$6.83M$11.18M$10.40M$21.03M$24.92M$30.35M
Total assets$25.10M$29.79M$34.02M$38.26M$44.82M$47.55M$52.42M$61.33M$66.98M$69.97M
Current assets$15.54M$19.99M$24.00M$28.21M$34.53M$37.10M$41.92M$50.99M$56.48M$60.94M
Total liabilities$5.86M$6.64M$6.17M$5.64M$8.18M$8.93M$9.57M$8.83M$8.73M$7.07M
Current liabilities$2.62M$3.23M$2.59M$1.90M$4.29M$4.90M$5.38M$4.35M$4.10M$3.59M
Total equity incl. NCI$19.25M$23.15M$27.85M$32.62M$36.64M$38.62M$42.85M$52.49M$58.25M$62.90M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M$1.34M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$514.00K$835.00K$604.00K$516.00K$618.00K$656.72K$497.15K$937.00K$662.00K$450.46K

Cash flow

Matinas BioPharma Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-312021-09-302021-06-30
Operating cash flow-$4.58M-$4.42M-$2.19M-$4.09M-$4.30M-$4.97MUnavailable-$3.96M-$5.75M-$864.66K
Capital expenditures$0$16.00KUnavailableUnavailable$42.00K$250.00KUnavailable$35.81K$224.00KUnavailable
Investing cash flow$2.96M$1.08M$6.20M$3.00M-$42.00K$5.75MUnavailable$56.65K$242.70K$7.65M
Financing cash flow-$1.00K-$1.00K-$1.00K-$4.00K-$5.00K-$3.00KUnavailable$8.33K-$8.32K$180.48K
Net change in cash-$1.62M-$3.34M$4.00M-$1.09M-$4.35M$777.00KUnavailable-$3.89M-$5.52M$6.97M
Stock-based compensation$1.27M$1.20M$1.21M$1.27M$1.34M$1.41M$1.22M$1.07M$1.06M$1.06M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$97.00K$98.00K$97.00K$93.00K$92.98K$89.00K$86.00K$65.00K$62.00K$59.00K

Derived

Matinas BioPharma Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-312021-09-302021-06-30
Free cash flow-$4.58M-$4.44MUnavailableUnavailable-$4.34M-$5.22MUnavailable-$3.99MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable-509.7%-515.5%-513.8%-557.4%UnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable-408.4%-491.1%UnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable116.1%126.1%132.9%114.3%UnavailableUnavailableUnavailable
Current ratio5.93x6.19x9.27x14.88x8.06x7.57x7.79x11.73x13.78x16.97x
Revenue YoY growth-100.0%-100.0%-100.0%UnavailableUnavailableUnavailableUnavailable-100.5%-100.0%Unavailable
Net marginUnavailableUnavailableUnavailable-503.0%-341.9%-513.8%-557.2%UnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable362.2%363.8%348.7%388.2%UnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable4.0%23.5%UnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MTNB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.